Correction to: The Cost Effectiveness of Genetic Testing for *CYP2C19* Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes

Laura Panattoni^{1,7} · Paul M. Brown^{1,2} · Braden Te Ao¹ · Mark Webster^{3,4} · Patrick Gladding^{3,5,6}

Published online: 21 January 2020
© Springer Nature Switzerland AG 2020

Correction to: PharmacoEconomics 2012; 30(11): 1067–1084
<https://doi.org/10.2165/11595080-000000000-00000>

Unfortunately, the article's Supplementary File Link is not working and the ESM material is missing from the published article. The correct version is updated here.

The original article can be found online at <https://doi.org/10.2165/11595080-000000000-00000>.

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s40273-020-00885-8>) contains supplementary material, which is available to authorized users.

✉ Laura Panattoni
laura.e.panattoni@gmail.com

¹ School of Population Health, University of Auckland, Auckland, New Zealand

² School of Social Sciences, Humanities and Arts, University of California, Merced, CA, USA

³ School of Medicine, University of Auckland, Auckland, New Zealand

⁴ Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand

⁵ Cleveland Clinic Foundation, Cleveland, OH, USA

⁶ Theranostics Laboratory, Cleveland, OH, USA

⁷ Department of Health Policy Research, Palo Alto Medical Foundation Research Institute, 2350 W. El Camino Real, Mountain View, California, CA 94040, USA